Sanofi boosts Lantus insulin production in Ireland
PARIS Feb 13 (Reuters) - French drugmaker Sanofi said on Wednesday it would invest 44 million euros ($59 million) on its site in Waterford, Ireland, to boost production of its top-selling insulin, Lantus.
The company, which has been reshuffling research and production sites in the United States and Europe after the patent loss of several key medicines, aims to start making Lantus at the site in 2016, Sanofi said in a statement.
Lantus is expected to continue its double-digit sales growth after the U.S. Food and Drug Administration this week refused to approve Novo Nordisk's rival insulin Tresiba until the Danish company conducts extra tests for potential heart risks.
- 'Good night': Haunting final contact from missing Malaysian jet |
- Crimeans vote over 90 percent to quit Ukraine for Russia |
- Ukraine, Russia agree Crimea truce until March 21-Ukraine minister
- North Korea fires 25 short-range and obsolete rockets: South Korea
- France bans Monsanto GM maize ahead of sowing season